{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:13:26Z","timestamp":1780380806372,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Juvenile dermatomyositis (JDM) is an uncommon autoimmune condition in children, often leading to prolonged disease burden and significant morbidity. Despite global advancements in understanding JDM, studies from the Middle East, particularly Oman, remain scarce. This study aims to characterize JDM from an Omani national cohort, evaluating clinical manifestations, laboratory features, disease course, and treatment outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective review of all JDM patients diagnosed and managed by pediatric rheumatologist in tertiary centers in Oman was conducted. Patient demographics, clinical features, laboratory findings, treatment modalities, and disease outcomes were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 30 children diagnosed with JDM were included. They had an equal female to male distribution, 1:1 ratio. The median age at disease onset was 6.78 years (range: 2\u201313), with a median diagnostic delay of 8.4 months (range:1\u201323). The median follow-up period for these patients was 4 years (absolute range: 1 month-16 years). Classic JDM skin manifestations, including heliotrope rash (<jats:italic>n<\/jats:italic>\u2009=\u200925; 83%) and Gottron\u2019s papules (<jats:italic>n<\/jats:italic>\u2009=\u200923; 77%), were common. Proximal muscle weakness was observed in 28 (93%) patients, while 23 (77%) patients exhibited elevated muscle enzymes. MRI findings consistent with myositis were present in 70% (<jats:italic>n<\/jats:italic>\u2009=\u200919\/27) of the subjects, and muscle biopsy confirmed JDM in 9 cases (30%). Among 25 patients tested for myositis specific antibodies, NXP2 (<jats:italic>n<\/jats:italic>\u2009=\u20093), Anti-TIF1 (<jats:italic>n<\/jats:italic>\u2009=\u20092), Anti-Mi-2 (<jats:italic>n<\/jats:italic>\u2009=\u20091), and MDA5 (<jats:italic>n<\/jats:italic>\u2009=\u20091) were detected, showing expected correlations with disease phenotype. Corticosteroids were universally administered, with methotrexate (<jats:italic>n<\/jats:italic>\u2009=\u200925; 83%) and IVIG (<jats:italic>n<\/jats:italic>\u2009=\u200915; 50%) as common adjuncts. Calcinosis was observed in 8 patients (27%), and was managed with various treatment modalities including pamidronate (<jats:italic>n<\/jats:italic>\u2009=\u20093), diltiazem (<jats:italic>n<\/jats:italic>\u2009=\u20092), and infliximab (<jats:italic>n<\/jats:italic>\u2009=\u20091). At the last follow-up, 18 patients (60%) were in clinical remission, 50% (<jats:italic>n<\/jats:italic>\u2009=\u200915) followed a polyphasic or chronic disease course, and 2 patients succumbed to disease-related complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study provides comprehensive characterization of pediatric JDM in Oman. The findings highlight regional variations in disease presentation, autoantibody profiles, and treatment responses, underscoring the need for early diagnosis and individualized management strategies. Continued follow-up is essential to optimize long-term outcomes and improve survival rates in this patient population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12969-025-01132-0","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:39:44Z","timestamp":1752777584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Juvenile dermatomyositis in Oman: clinical patterns and disease trajectory from a National cohort"],"prefix":"10.1186","volume":"23","author":[{"given":"Reem","family":"Abdwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadev J.","family":"Mal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Al Masroori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqaiya","family":"Al Jashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiya Al","family":"Abrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Al-Zakwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995\u20131998: results from the National Institute of arthritis and musculoskeletal and skin diseases registry. Arthritis Rheum. 2003;49:300\u20135. https:\/\/doi.org\/10.1002\/art.11122.","journal-title":"Arthritis Rheum"},{"key":"1132_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s11926-011-0167-9","volume":"13","author":"M Batthish","year":"2011","unstructured":"Batthish M, Feldman BM. Juvenile dermatomyositis. Curr Rheumatol Rep. 2011;13:216\u201324. https:\/\/doi.org\/10.1007\/s11926-011-0167-9.","journal-title":"Curr Rheumatol Rep"},{"key":"1132_CR3","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(08)60955-1.","journal-title":"Lancet"},{"key":"1132_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/rheumatology\/ken038","volume":"47","author":"C Manlhiot","year":"2008","unstructured":"Manlhiot C, Liang L, Tran D, Bitnun A, Tyrrell PN, Feldman BM. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford). 2008;47:526\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/ken038.","journal-title":"Rheumatology (Oxford)"},{"key":"1132_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/acr.22358","volume":"66","author":"MAM Orione","year":"2014","unstructured":"Orione MAM, Silva CA, Sallum AME, Campos LMA, Omori CH, Braga ALF, et al. Risk factors for juvenile dermatomyositis: exposure to tobacco and air pollutants during pregnancy. Arthritis Care Res (Hoboken). 2014;66:1571\u20135. https:\/\/doi.org\/10.1002\/acr.22358.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1132_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/art.21068","volume":"53","author":"LM Pachman","year":"2005","unstructured":"Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of arthritis and musculoskeletal and skin diseases research registry. Arthritis Rheum. 2005;53:166\u201372. https:\/\/doi.org\/10.1002\/art.21068.","journal-title":"Arthritis Rheum"},{"key":"1132_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0889-857X(02)00024-8","volume":"28","author":"AV Ramanan","year":"2002","unstructured":"Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28:833\u201357. https:\/\/doi.org\/10.1016\/S0889-857X(02)00024-8.","journal-title":"Rheum Dis Clin North Am"},{"key":"1132_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","volume":"48","author":"H Sanner","year":"2009","unstructured":"Sanner H, Gran JT, Sjaastad I, Flat\u00f8 B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford). 2009;48:1541\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kep302.","journal-title":"Rheumatology (Oxford)"},{"key":"1132_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/MPH.0b013e3181bf29a2","volume":"32","author":"P Morris","year":"2010","unstructured":"Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol. 2010;32:189\u201391.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1132_CR10","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/rheumatology\/kel219","volume":"45","author":"VE Brown","year":"2006","unstructured":"Brown VE, Pilkington CA, Feldman BM, Davidson JE. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45:990\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/kel219.","journal-title":"Rheumatology (Oxford)"},{"key":"1132_CR11","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al. 2017 European league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69:1955\u201364. https:\/\/doi.org\/10.1002\/art.40320.","journal-title":"Arthritis Rheumatol"},{"key":"1132_CR12","first-page":"115","volume":"17","author":"R Shehata","year":"1999","unstructured":"Shehata R, Al-Mayouf S, Al-Dalaan A, Al-Mazaid A, Al-Balaa S, Bahabri S. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol. 1999;17:115\u20138. PMID: 10084045.","journal-title":"Clin Exp Rheumatol"},{"key":"1132_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s13312-013-0260-4","volume":"50","author":"PR Chickermane","year":"2013","unstructured":"Chickermane PR, Mankad D, Khubchandani RP. Disease patterns of juvenile dermatomyositis from Western India. Indian Pediatr. 2013;50:961\u20133.","journal-title":"Indian Pediatr"},{"key":"1132_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jpeds.2017.01.046","volume":"184","author":"K Phillippi","year":"2017","unstructured":"Phillippi K, Hoeltzel M, Byun Robinson A, Kim S, Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators. Race, income, and disease outcomes in juvenile dermatomyositis. J Pediatr. 2017;184:38\u201344. https:\/\/doi.org\/10.1016\/j.jpeds.2017.01.046. PMID: 28410093; PMCID: PMC5410644..e1.","journal-title":"J Pediatr"},{"key":"1132_CR15","doi-asserted-by":"publisher","unstructured":"El-Garf K, El-Garf A, Salah S, Marzouk H, Farag Y, Mostafa N. (2022) Juvenile dermatomyositis: demographics, characteristics and disease outcome in an Egyptian cohort. Clin Exp Rheumatol 40:450\u2013456. https:\/\/doi.org\/10.55563\/clinexprheumatol\/h0s7tq. PMID: 34369367.","DOI":"10.55563\/clinexprheumatol\/h0s7tq"},{"key":"1132_CR16","doi-asserted-by":"publisher","unstructured":"Malek A, Raeeskarami SR, Ziaee V, Aghighi Y, Moradinejad MH. (2014) Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis. Clin Rheumatol 33:1113\u20131118. https:\/\/doi.org\/10.1007\/s10067-014-2675-2. PMID: 24878926.","DOI":"10.1007\/s10067-014-2675-2"},{"key":"1132_CR17","doi-asserted-by":"publisher","unstructured":"Al-Mayouf SM, AlMutiari N, Muzaffer M, Shehata R, Al-Wahadneh A, Abdwani R, Al-Abrawi S, Abu-Shukair M, El-Habahbeh Z, Alsonbul A. (2017) Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int 37:1513\u20131517. https:\/\/doi.org\/10.1007\/s00296-017-3770-x. PMID: 28685324.","DOI":"10.1007\/s00296-017-3770-x"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","volume":"72","author":"D Lazarevic","year":"2013","unstructured":"Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013;72:686\u201393.","journal-title":"Ann Rheum Dis"},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"152104","DOI":"10.1016\/j.semarthrit.2022.152104","volume":"57","author":"P Cancarini","year":"2022","unstructured":"Cancarini P, Nozawa T, Whitney K, Bell-Peter A, Marcuz JA, Taddio A, Guo J, Dover S, Feldman BM. The clinical features of juvenile dermatomyositis: a single-centre inception cohort. Semin Arthritis Rheum. 2022;57:152104. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152104.","journal-title":"Semin Arthritis Rheum"},{"key":"1132_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-022-00709-3","volume":"20","author":"J Neely","year":"2022","unstructured":"Neely J, Ardalan K, Huber A, Kim S, Childhood Arthritis and Rheumatology Research Alliance Investigators. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new childhood arthritis and rheumatology research alliance registry. Pediatr Rheumatol Online J. 2022;20:50.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1132_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10067-016-3530-4","volume":"36","author":"K Barut","year":"2017","unstructured":"Barut K, Aydin PO, Adrovic A, Sahin S, Kasapcopur O. Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol. 2017;36:361\u20136. https:\/\/doi.org\/10.1007\/s10067-016-3530-4.","journal-title":"Clin Rheumatol"},{"key":"1132_CR22","doi-asserted-by":"publisher","unstructured":"Nitiyarom R, Charuvanij S, Likasitwattanakul S, Thanoophunchai C, Wisuthsarewong W. (2022) Juvenile dermatomyositis in Thai children: retrospective review of 30 cases from a tertiary care center. Indian J Dermatol Venereol Leprol 88:162\u2013170. https:\/\/doi.org\/10.25259\/IJDVL_297_20. PMID: 34491668.","DOI":"10.25259\/IJDVL_297_20"},{"key":"1132_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12969-016-0118-0","volume":"14","author":"LO Okong\u2019o","year":"2016","unstructured":"Okong\u2019o LO, Esser M, Wilmshurst J, Scott C. Characteristics and outcome of children with juvenile dermatomyositis in cape town: a cross-sectional study. Pediatr Rheumatol Online J. 2016;14:60. https:\/\/doi.org\/10.1186\/s12969-016-0118-0. PMID: 27835954; PMCID: PMC5106783.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1132_CR24","doi-asserted-by":"publisher","unstructured":"Mehta P, Lawrence A, Gupta L, Misra DP, Agarwal V, Misra R, Aggarwal A. (2024) Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: a real-world experience from a low-middle income country. Rheumatol Int 44:3035\u20133040. https:\/\/doi.org\/10.1007\/s00296-023-05377-4. PMID: 37405442.","DOI":"10.1007\/s00296-023-05377-4"},{"key":"1132_CR25","doi-asserted-by":"publisher","unstructured":"Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C, Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance. (2012) Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 64:546\u2013553. https:\/\/doi.org\/10.1002\/acr.20695. PMID: 22076847; PMCID: PMC3315594.","DOI":"10.1002\/acr.20695"},{"key":"1132_CR26","doi-asserted-by":"publisher","unstructured":"Sharma A, Gupta A, Rawat A, Suri D, Singh S. (2020) Long-term outcome in children with juvenile dermatomyositis: a single-center study from north India. Int J Rheum Dis 23:392\u2013396. https:\/\/doi.org\/10.1111\/1756-185X.13759. PMID: 31793219.","DOI":"10.1111\/1756-185X.13759"},{"key":"1132_CR27","doi-asserted-by":"publisher","unstructured":"Huber A, Feldman BM. (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7:441\u2013446. https:\/\/doi.org\/10.1007\/s11926-005-0048-1. PMID: 16303103.","DOI":"10.1007\/s11926-005-0048-1"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01132-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01132-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:37:19Z","timestamp":1757252239000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01132-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01132-0","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Sultan Qaboos University (MREC # 3430\/ November 18, 2024, with waiver of consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"declaration: Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"75"}}